TRPC4 and prostate carcinoma: Copy number alterations were also observed rarely with the exception of the amplification of TRPA1, which was amplified in 7.2% of prostate cancers in TCGA, and of TRPC4 and TRPC3, which were homodeleted in 5.9% and 2.5% of cases, respectively.